Nimodipine-d7

• Description :

  Nimodipine-d7 is the deuterium labeled Nimodipine. Nimodipine (BAY-e 9736) is an orally active, well-tolerated and light-sensitive dihydropyridine calcium antagonist. Nimodipine can be used for the research of cerebrovascular disorders[1].

• Product Name Alternative :

  BAY-e 9736-d7

• UNSPSC :

  12352005

• Hazard Statement :

  H302, H315, H319, H335

• Target :

  Autophagy; Calcium Channel; Isotope-Labeled Compounds

• Type :

  Isotope-Labeled Compounds

• Related Pathways :

  Autophagy; Membrane Transporter/Ion Channel; Neuronal Signaling; Others

• Field of Research :

  Cardiovascular Disease; Cancer

• Purity :

  99.35

• Solubility :

  DMSO : 100 mg/mL (ultrasonic; warming)

• Smiles :

  O=C(C1=C(C)NC(C)=C(C(OC(C([2H])([2H])[2H])([2H])C([2H])([2H])[2H])=O)C1C2=CC=CC([N+]([O-])=O)=C2)OCCOC

• Molecular Formula :

  C21H19D7N2O7

• Molecular Weight :

  425.48

• Precautions :

  H302, H315, H319, H335

• References & Citations :

  [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216. |[2]Langley, M.S., et al. Nimodipine. Drugs 37, 669–699 (1989) .|[3] Marbacher S, et al. Prevention of delayed cerebral vasospasm by continuous intrathecal infusion of glyceroltrinitrate and nimodipine in the rabbit model in vivo. Intensive Care Med. 2008;34 (5) :932-938.|[4]Honn KV, et al. Inhibition of tumor cell-platelet interactions and tumor metastasis by the calcium channel blocker, nimodipine. Clin Exp Metastasis. 1984;2 (1) :61-72.

• Shipping Conditions :

  Blue Ice

• Storage Conditions :

  -20°C, 3 years (Powder)

• Scientific Category :

  Isotope-Labeled Compounds

• Clinical Information :

  No Development Reported

• CAS Number :

  [1246815-36-0]